Department of Obstetrics and Gynecology, Medical Center, University of Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Mol Diagn Ther. 2020 Apr;24(2):215-232. doi: 10.1007/s40291-020-00453-y.
Breast cancer (BC) is the most frequent malignant disease in women worldwide and is therefore challenging for the healthcare system. Early BC detection remains a leading factor that improves overall outcome and disease management. Aside from established screening procedures, there is a constant demand for additional BC detection methods. Routine BC screening via non-invasive liquid biopsy biomarkers is one auspicious approach to either complete or even replace the current state-of-the-art diagnostics. The study explores the diagnostic potential of urinary exosomal microRNAs with specific BC biomarker characteristics to initiate the potential prospective application of non-invasive BC screening as routine practice.
Based on a case-control study (69 BC vs. 40 healthy controls), expression level quantification and subsequent biostatistical computation of 13 urine-derived microRNAs were performed to evaluate their diagnostic relevance in BC.
Multilateral statistical assessment determined and repeatedly confirmed a specific panel of four urinary microRNA types (miR-424, miR-423, miR-660, and let7-i) as a highly specific combinatory biomarker tool discriminating BC patients from healthy controls, with 98.6% sensitivity and 100% specificity.
Urine-based BC diagnosis may be achieved through the analysis of distinct microRNA panels with proven biomarker abilities. Subject to further validation, the implementation of urinary BC detection in routine screening offers a promising non-invasive alternative in women's healthcare.
乳腺癌(BC)是全球女性最常见的恶性疾病,因此对医疗保健系统构成挑战。早期 BC 的检测仍然是改善整体预后和疾病管理的主要因素。除了既定的筛查程序外,人们一直需要额外的 BC 检测方法。通过非侵入性液体活检生物标志物进行常规 BC 筛查是一种很有前途的方法,可以完全或甚至取代当前的最先进诊断方法。本研究探讨了具有特定 BC 生物标志物特征的尿外泌体 microRNAs 的诊断潜力,以启动非侵入性 BC 筛查作为常规实践的潜在前瞻性应用。
基于病例对照研究(69 例 BC 与 40 例健康对照),对 13 种尿液衍生 microRNAs 的表达水平进行定量,并进行后续的生物统计学计算,以评估其在 BC 中的诊断相关性。
多方面的统计评估确定并反复证实了一组特定的四种尿 microRNA 类型(miR-424、miR-423、miR-660 和 let7-i)作为一种高度特异性的组合生物标志物工具,可将 BC 患者与健康对照区分开来,其敏感性为 98.6%,特异性为 100%。
通过分析具有已证明的生物标志物能力的特定 microRNA 组,可以实现基于尿液的 BC 诊断。在进一步验证的基础上,在常规筛查中实施尿液 BC 检测为女性健康提供了一种有前途的非侵入性替代方法。